The role of nutraceuticals in the treatment of primary dyslipidemia

Hellenic J Cardiol. 2020 Jan-Feb;61(1):60-62. doi: 10.1016/j.hjc.2018.07.009. Epub 2018 Aug 7.

Authors

Elias Sanidas¹, Charalampos Grassos²

Affiliations

¹ Hypertension Excellence Centre - ESH, Dept. of Cardiology, LAIKO General Hospital, Athens, Greece. Electronic address: [email protected].
² Hypertension Excellence Centre - ESH, Dept. of Cardiology, KAT General Hospital, Athens, Greece.

PMID: 30092273
DOI: 10.1016/j.hjc.2018.07.009

No abstract available

Keywords: Cholesterol; Dyslipidemia; Nutraceuticals.

Publication types

Comparative Study
Letter

MeSH terms

Adult
Anticholesteremic Agents / therapeutic use
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / mortality*
Cholesterol / blood
Combined Modality Therapy
Diet, Healthy / methods*
Diet, Healthy / statistics & numerical data
Dietary Supplements / adverse effects*
Dietary Supplements / supply & distribution
Dyslipidemias / diet therapy
Dyslipidemias / drug therapy*
Ezetimibe / therapeutic use
Female
Humans
Lipoproteins, LDL / blood
Male
Meta-Analysis as Topic
Middle Aged
Risk Factors
Treatment Outcome

Substances

Anticholesteremic Agents
Lipoproteins, LDL
Cholesterol
Ezetimibe